Mesothelioma is a type of late‐onset cancer that develops in cells covering the outer surface
of organs. Although it can affect the peritoneum, heart, or testicles, it mainly targets the lining …

Background In patients with advanced melanoma, immune‐checkpoint inhibitors (ICIs)
represent the mainstay for first line treatment. Recently, relatlimab+ nivolumab was …

We assessed the murine Stimulator of Interferon Genes (STING) agonist, DMXAA, for anti-
mesothelioma potential using the AE17-sOVA model that expresses ovalbumin (OVA) as a …

Objectives Malignant pleural mesothelioma (MPM) is an aggressive disease with grim
prognosis due to lack of effective treatment options. Disease prediction in association with …

Simple Summary Many clinical trials have investigated the role of Immune Checkpoint
Inhibitors (ICIs) in pleural mesothelioma (PM), with contrasting results. We performed a …

In this commentary, using existing clinical trial data and FDA approvals we propose that
there is currently a critical need for an appropriate balancing between the financial impact of …

Introduction Despite increased attention on immunotherapy, primarily immune checkpoint
blockade, as a therapeutic approach for mesothelioma (MMe), its efficacy and tolerability …

Malignant pleural mesothelioma (MPM) is a fatal disease of respiratory system. Despite the
availability of invasive biomarkers with promising results, there are still significant diagnostic …

Simple Summary Only a limited number of murine mesothelioma cell lines have been
developed to date. We sought to expand this number and to characterize the models in …

Objective This paper presents a preliminary experience based on the" one-to-many"
approach of the Shiny method. Numerous (or" many") treatments for advanced or metastatic …